Smith & Nephew plc (ADR)  

(Public, NYSE:SNN)   Watch this stock  
Find more results for SNN
59.94
+1.00 (1.70%)
Real-time:   1:43PM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 59.40 - 59.98
52 week 44.84 - 60.22
Open 59.48
Vol / Avg. 16,453.00/60,136.00
Mkt cap 10.85B
P/E 14.78
Div/yield 0.81/2.18
EPS 4.05
Shares 180.95M
Beta 0.65
Inst. own 3%
Aug 1, 2013
Q2 2013 And Half Year Smith & Nephew Earnings Release Add to calendar
May 2, 2013
Q1 2013 Smith & Nephew Earnings Release
Apr 11, 2013
Smith & Nephew Annual Shareholder Meeting
Mar 19, 2013
Smith & Nephew at Canaccord Genuity Musculoskeletal Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin 13.18% 17.62%
Operating margin 19.78% 20.45%
EBITD margin - 30.02%
Return on average assets 10.71% 14.03%
Return on average equity 15.14% 20.62%
Employees 10,477 -
Carbon Disclosure Rating - 84/100

Address

15 Adam Street
LONDON, ENG WC2N 6LA
United Kingdom - Map
+44-20-74017646 (Phone)
+44-20-79303353 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (which includes arthroscopic procedures referred to as sports medicine) and advanced wound management. It operates in three segments: Orthopaedics, Endoscopy and Advanced Wound Management. It operates on a worldwide basis and has distribution channels in over 90 countries. Orthopaedic reconstruction implants include hip, knee and shoulder joints, as well as ancillary products, such as bone cement and mixing systems used in cemented reconstruction joint surgery. Endoscopy business develops and commercialises endoscopic (minimally invasive surgery) techniques, educational programmes and services. Advanced Wound Management business offers a range of products from initial wound bed preparation through to full wound closure. In May 2012, it acquired Kalypto Medical, Inc. In December 2012, the Company acquired the assets of Healthpoint Biotherapeutics.

Officers and directors

Olivier Bohuon Chief Executive Officer, Executive Director
Age: 54
Bio & Compensation  - Reuters
Julie Brown Chief Financial Officer, Executive Director
Age: 50
Bio & Compensation  - Reuters
Michael Frazzette President - Advanced Surgical Devices
Age: 50
Bio & Compensation  - Reuters
Kelvin Johnson President - International Markets
Age: 61
Bio & Compensation  - Reuters
Roger Teasdale President - Advanced Wound Management
Age: 45
Bio & Compensation  - Reuters
Francisco Canal Vega President - Emerging Markets
Age: 51
Bio & Compensation  - Reuters
R. Gordon Howe Senior Vice President - Global Planning and Development
Age: 50
Bio & Compensation  - Reuters
Ros Rivaz Chief Technology Officer
Age: 57
Bio & Compensation  - Reuters
John W. Campo Chief Legal Officer
Age: 58
Bio & Compensation  - Reuters
Helen Maye Chief Human Resources Officer
Age: 53
Bio & Compensation  - Reuters